ARTV · Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Market Cap
186.9M
52 Wk Range
$2.96 - $14.53
Previous Close
$3.83
Open
$3.82
Volume
1,775,381
Day Range
$3.77 - $3.93
Enterprise Value
-120.6M
Cash
319.1M
Avg Qtr Burn
-28.45M
Insider Ownership
14.43%
Institutional Own.
83.61%
Qtr Updated
Sep 30th 2026
